- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc stock price live, this page displays NASDAQ BEAM stock exchange data. View the BEAM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Beam Therapeutics Inc real time stock price chart below.
What Is the Beam Therapeutics Inc Stock Price Today?
The Beam Therapeutics Inc stock price today is 24.50.
What Is the Stock Symbol for Beam Therapeutics Inc?
The stock symbol for Beam Therapeutics Inc is "BEAM."
What Stock Exchange Does Beam Therapeutics Inc Trade On?
Beam Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Beam Therapeutics Inc a Good Stock to Buy?
Determining whether Beam Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BEAM quote. (ISIN: US07373V1052)
What Is the Beam Therapeutics Inc Stock Price Today?
The Beam Therapeutics Inc stock price today is 24.50.
What Is the Stock Symbol for Beam Therapeutics Inc?
The stock symbol for Beam Therapeutics Inc is "BEAM."
What Stock Exchange Does Beam Therapeutics Inc Trade On?
Beam Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Beam Therapeutics Inc a Good Stock to Buy?
Determining whether Beam Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BEAM quote. (ISIN: US07373V1052)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.21
25.48
52 wk Range
20.23
38.26
BEAM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.2125.48
52 wk Range
20.2338.26
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BEAM Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
52.15
Upside
+112.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Analyst Ratings
13 Buy
2 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 52.15
(+112.87% Upside)
Beam Therapeutics Inc Earnings Call Summary for Q4/2025
- Beam Therapeutics stock rose 5.37% in premarket trading to $29.85 following Q4 2025 results and strategic announcements.
- Company secured $500M non-dilutive financing with Sixth Street Partners, extending cash runway into mid-2029 with $1.25B in cash.
- Significant progress reported in PKU program BEAM-304, with IND filing planned for 2026; focus on risto-cel commercialization continues.
- Strong liquidity position maintained with current ratio of 6.02 and more cash than debt; stock delivered 70% return over past six months.
- Management emphasized strategic capital allocation for pipeline growth while navigating regulatory pathways and competitive genetic therapy market.
Last Updated: 2026-02-24, 09:30 a/m
Read Full TranscriptEarnings
Latest Release
Aug 04, 2026
EPS / Forecast
-1.18 / -1.10
Revenue / Forecast
490K / 15.88M
Compare BEAM to Peers and Sector
Metrics to compare | BEAM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBEAMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −28.3x | −0.9x | −0.4x | |
PEG Ratio | −0.35 | −0.07 | 0.00 | |
Price/Book | 2.3x | 3.3x | 2.6x | |
Price / LTM Sales | 15.7x | 4.4x | 3.0x | |
Upside (Analyst Target) | 112.9% | 309.0% | 58.2% | |
Fair Value Upside | Unlock | 22.7% | 7.7% | Unlock |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Beam (BEAM) Stock Price Today?
The Beam stock price today is 24.50 USD.
What Stock Exchange Does Beam Trade On?
Beam is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Beam?
The stock symbol for Beam is "BEAM."
What Is the Beam Market Cap?
As of today, Beam market cap is 2.45B USD.
What Is Beam's Earnings Per Share (TTM)?
The Beam EPS (TTM) is -0.84.
When Is the Next Beam Earnings Date?
Beam will release its next earnings report on Nov 09, 2026.
From a Technical Analysis Perspective, Is BEAM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Beam Stock Split?
Beam has split 0 times.
How Many Employees Does Beam Have?
Beam has 540 employees.
What is the current trading status of Beam (BEAM)?
As of Oct 04, 2026, Beam (BEAM) is trading at a price of 24.50 USD, with a previous close of 24.50 USD. The stock has fluctuated within a day range of 24.21 USD to 25.48 USD, while its 52-week range spans from 20.23 USD to 38.26 USD.
What Is Beam (BEAM) Price Target According to Analysts?
The average 12-month price target for Beam is 52.15 USD, with a high estimate of 80 USD and a low estimate of 26 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +112.87% Upside potential.
What Is the BEAM Premarket Price?
BEAM's last pre-market stock price is 25.16 USD. The pre-market share volume is 16,300.00, and the stock has decreased by 0.77, or 3.16%.
What Is the BEAM After Hours Price?
BEAM's last after hours stock price is 24.55 USD, the stock has decreased by 0.05, or 0.20%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.